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ABSTRACT 
Disturbances in the lipid homeostasis can result in a wide variety of different diseases 
and symptoms. This thesis is focused on the regulation of cholesterol metabolism and 
its relation to atherosclerosis development, and the effect of mitochondrial (mt)DNA 
depletion on hepatic β-oxidation of fatty acids.  
ApoE deficient mice spontaneously develop atherosclerosis due to 
accumulation of chylomicron remnants in the circulation, a process highly dependent 
on intestinal cholesterol absorption. The lack of functional ApoE prevents receptor 
mediated uptake of lipoproteins, leading to very high levels of circulating cholesterol. 
We used two approaches to test the influence of plasma cholesterol levels on 
atherosclerosis development in ApoE deficient mice. In paper I we disrupted the 
Cyp8b1 gene to disable the endogenous synthesis of cholic acid and thereby reduce the 
intestinal absorption of cholesterol. Cyp8b1/ApoE double knockout mice displayed 
reduced atherosclerotic lesions in aorta, reduced cholesterol levels in plasma and liver 
and reduced intestinal cholesterol absorption compared to ApoE knockout mice. In 
paper II we treated ApoE deficient mice with the thyroid receptor β modulator GC-1. 
Supplementation with thyroid hormone reduces plasma cholesterol in humans and 
rodents; this effect is mediated by the thyroid receptor isoform β (TRβ). We found that 
oral administration of GC-1 reduced atherosclerosis after 20 weeks of treatment. This 
reduction was accompanied by increased hepatic LDL-receptor expression, bile acid 
synthesis and fecal bile acid excretion, but serum cholesterol levels were not reduced. 
The onset and development of atherosclerosis was likely delayed by short-term (one to 
ten weeks) treatment effects, such as increased fecal excretion of neutral sterols, 
reduced intestinal cholesterol absorption and reduced plasma cholesterol levels, which 
were not significant after long-term (20 weeks) treatment.  
Increased HDL-cholesterol and reduced intestinal cholesterol absorption 
may lead to improved anti-atherosclerotic effects on cholesterol metabolism, but the 
LXR-induced increase in HDL-cholesterol may depend on the intestinal cholesterol 
absorption. In paper III we investigated this by oral administration of the LXR agonist 
GW3965 and the cholesterol absorption inhibitor ezetimibe. The combined treatment 
effectively reduced the intestinal cholesterol absorption and increased serum HDL-
cholesterol and ApoAI. Neither intestinal nor hepatic ABCA1 protein expression 
increased, but hepatic ApoaI expression was induced. The LXR-driven increase in 
HDL-cholesterol and ApoAI was thus independent of both intestinal cholesterol 
absorption and increased intestinal or hepatic ABCA1 protein. The combined treatment 
effectively increased fecal excretion of cholesterol. 
Thymidine kinase (TK) 2 deficiency leads to mtDNA depletion. TK2 
deficient mice have been developed and display symptoms of defect fat metabolism. 
In paper IV we studied the lipid phenotype of TK2 deficient mice in search for 
treatment options. TK2 deficient mice displayed elevated plasma levels of cholesterol, 
free fatty acids and long-chain acylcarnitines. In mice with hepatic mtDNA levels 
below 20%, the blood sugar and the ketone levels dropped. These mice also exhibited 
reduced hepatic mitochondrial β-oxidation and CPT activity, indicating reduced 
capacity to metabolize long-chain acylcarnitines. Hepatic ATP synthesis rates were 
unaltered in 14 days old TK2 deficient mice compared to controls. 
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1 INTRODUCTION 
 
1.1  LIPIDS 
Lipids represent both polar and non-polar molecules that are involved in a multitude of 
functions in our bodies. This thesis is focused on the metabolism of two types of lipids; 
cholesterol and fatty acids.  
 
1.1.1 Cholesterol 
Cholesterol is a 27 carbon structure that functions as a component of cellular 
membranes; affecting membrane fluidity, and as a precursor for steroid hormones and 
bile acids (figure 1). Cholesterol is essential for mammalian life, but as for most things 
in life, excess levels can cause disease. 
 
 
 
Figure 1. The chemical structure of cholesterol. 
 
1.1.1.1 Hepatic cholesterol metabolism 
The cells in our bodies can acquire cholesterol either by synthesis or by uptake of 
cholesterol from lipoproteins circulating in the blood stream (see section 1.1.3). The 
liver is a central organ for cholesterol metabolism where many of the plasma 
lipoproteins are formed and metabolized. The liver contributes 20-25 % of the total 
daily cholesterol synthesis. The synthesis starts with the condensation of acetyl-
coenzyme A (Acetyl-CoA) to form mevalonate, a six carbon intermediate. This 
requires two important enzymes; 3-hydroxy-3-methyl-glutaryl-Coenzyme A (Hmg-
CoA) reductase and –synthase, of which the former is the rate-limiting enzyme of 
cholesterol synthesis and the target of statins [1]. The endogenous cholesterol synthesis 
is regulated by the sterol regulatory element binding protein (SREBP) 2 which 
responds to intracellular cholesterol levels. When levels are high, SREBP2 is found in 
the endoplasmic reticulum (ER) as an inactive precursor, but as cholesterol levels 
decrease, SREBP-2 moves to the Golgi where it is proteolytically cleaved. The 
cytoplasmic portion of the peptide then moves into the nucleus where it binds to sterol 
response elements (SRE) in the promoter region and activates transcription of genes 
involved in cholesterol synthesis [2]. Within the cells, cholesterol is stored as 
cholesteryl esters (one cholesterol molecule bound to one fatty acid by an ester bond). 
Esterification is carried out by Acyl-CoA: cholesterol acyltransferase (ACAT) 1 and 2. 
ACAT 1 is ubiquitously expressed, while ACAT 2 is expressed only in enterocytes and 
 2 
hepatocytes [3, 4]. Free cholesterol can be excreted from the liver into the bile via the 
ATP-binding cassette (ABC) G5/G8 heterodimer. Once formed, the cholesterol ring-
structure is very stable and not easily metabolized. Therefore, formation of bile acids in 
the liver constitutes one of the major elimination routes of cholesterol from the body.  
 
Bile acid synthesis requires an array of enzymes belonging to the 
Cytochrome P450 (CYP) superfamily. Formation of bile acids can occur through two 
pathways, often denoted as the classic and the alternative pathway. The classic pathway 
starts with hydroxylation of the 7α position in the cholesterol ring structure. This step is 
carried out by the enzyme encoded for by the cholesterol 7α-hydroxylase (Cyp7a1) 
gene and is the rate limiting step in bile acid synthesis. The classic pathway results in 
formation of either cholic acid (CA) or chenodeoxy cholic acid (CDCA) (figure 2), the 
two primary bile acids in humans. CA and CDCA have a common precursor; 7α-
hydroxy-4-cholestene-3-one (C4), which can be hydroxylated in the C12 position by 
sterol 12α-hydroxylase (CYP8B1) and form CA. Alternatively, without 12α-
hydroxylation, it is converted to CDCA. The alternative pathway is initiated by sterol 
27-hydroxylase (CYP27A1) and results in formation of CDCA. Bile acid synthesis in 
mice differs slightly from that in humans as most of the synthesized CDCA is 
converted into muricholic acids (MCAs) [5] (figure 2 and 3).  
 
                  
 
Figure 2. An overview of the main steps in bile acid synthesis. 
 
                   A                                            B                                             C 
 
 
Figure 3. The chemical structures of the unconjugated primary bile acids in humans and mice:  
(A) cholic acid, (B) chenodeoxycholic acid and (C) muricholic acid. Bile acids are conjugated to taurine 
or glycine at the carboxylic acid side chain. 
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Because of this, the bile acid pool in mice is more hydrophilic than in humans. Bile 
acids are amphipathic molecules containing the same ring structure as cholesterol, but 
they are more hydrophilic than cholesterol and therefore have increased solubility in 
water. This property is important for transport of cholesterol in the bile and for 
solubilizing fats in the intestine. Primary bile acids are conjugated to either taurine or 
glycine at their carboxylic acid side chains, which lowers their pKa and optimizes their 
capabilities as emulsifiers. In mice, bile acids are mainly conjugated to taurine, while 
glycine-conjugates dominate in humans [6, 7]. During fasting periods, the bile acids are 
excreted to and collected in the gallbladder together with cholesterol and phospholipids, 
forming bile. The bile is released from the gallbladder into the proximal small intestine 
when food is ingested. Bile acids undergo enterohepatic circulation that preserves the 
bile acid pool as the major part of bile acids are re-absorbed in ileum and re-circulated 
to the liver. Bile acids and cholesterol exist in an intimate interplay, affecting synthesis 
rates, uptake and excretion of each other. The enterohepatic circulation (figure 4) 
facilitates this regulation by stimulating nuclear receptors such as the liver x receptor 
(LXR) and the farnesoid x receptor (FXR) (see section 1.3). 
 
1.1.1.2 Intestinal cholesterol metabolism 
The absorption of dietary cholesterol is believed to occur mainly in the jejunum of the 
small intestine and depends on bile composition and the amount of ingested cholesterol. 
Conjugated bile acids act as emulsifiers in the small intestine and form micelles 
together with cholesterol, phospholipids and other fats. In mice, the ratio of CA to β-
MCA seems to be of importance for the emulsification of cholesterol [8]. CA-depletion 
in mice, due to disruption of Cyp8b1, leads to decreased intestinal cholesterol 
absorption. Contrary, dietary supplementation with CA increases intestinal cholesterol 
absorption [9, 10].  
 
Several protein transporters are involved in the process of uptake and trafficking of 
cholesterol through the enterocyte. In 2004 the Niemann-Pick C1 Like 1 (NPC1L1) 
protein was shown to be critical for intestinal cholesterol absorption [11] and soon after 
it was also shown to be the target of the cholesterol absorption inhibitor ezetimibe [12]. 
NPC1L1 locates to the apical brush border membrane of intestinal enterocytes in mice 
and humans. Importantly, humans also express this protein in hepatocytes while the 
expression in mouse liver is very low [13]. Cholesterol binds to NPC1L1 and is 
subsequently incorporated into the enterocyte in clathrin-coated vesicles. Ezetimibe 
blocks the NPC1L1-mediated uptake of cholesterol by inhibiting the vesicular 
internalization of NPC1L1 [14]. Cholesteryl esters entering the small intestine are 
hydrolyzed by pancreatic enzymes before uptake and ezetimibe blocks the absorption 
of the free cholesterol formed after hydrolysis, but not the fatty acid moieties [15]. 
After uptake into the enterocyte by NPC1L1, the major part of cholesterol is esterified 
by ACAT2 and incorporated into chylomicrons. However, part of the internalized 
cholesterol can be transferred as free cholesterol to HDL via ABCA1. The small 
intestine may contribute up to 30 % of the total HDL-cholesterol in mice [16]. The 
ABCG5/G8 heterodimer balances the uptake of cholesterol via NPC1L1 by pumping 
free cholesterol back to the intestinal lumen (figure 4).  
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Figure 4. A schematic overview of the enterohepatic circulation of cholesterol. FC = free cholesterol, CE 
= cholesteryl esters, BA = bile acids. 
 
1.1.2 Fatty acids 
Fatty acids function as a source of energy; the break-down of fatty acids through β-
oxidation is the first step in a process that yields a large quantity of adenosine 
triphosphate (ATP). They also function as cell membrane components and signaling 
molecules. Fatty acids are carbon-chain structures with a carboxylic acid at one end and 
they are classified by the length and number of double-bonds in the aliphatic tail. The 
hydrophobicity of the structure increases with increasing tail length. Most of the 
naturally occurring fatty acids have an even number of carbon atoms in their aliphatic 
tail. Fatty acids containing one or more double-bonds are classified as unsaturated fatty 
acids, while saturated fatty acids contain no double-bonds (figure 5). 
 
A                                                                              B 
       
 
Figure 5. The chemical structures of two fatty acids.  
(A) Palmitic acid (C16:0); a saturated fatty acid, (B) Palmitoleic acid (C16:1 n-7); an unsaturated fatty 
acid. 
 
1.1.2.1 Hepatic fatty acid metabolism 
The liver acquires fatty acids through synthesis within the cells (lipogenesis), 
absorption from dietary sources in the intestine or catabolism of stored triacylglycerol 
(TAG) in adipose tissue (lipolysis), which releases fatty acids into the blood stream. 
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The regulation of lipolysis in white adipose tissue is complex and many regulatory 
factors have been identified, but the hormonal regulation by insulin and catecholamines 
via hormone sensitive lipase (HSL) and the more recently identified adipose 
triglyceride lipase (ATGL) is well described [17, 18].  
 
Lipogenesis takes place in the cytoplasm of the cells and requires malonyl-CoA, which 
is formed by carboxylation of acetyl-CoA through interaction with acetyl-CoA 
carboxylase (ACC). Malonyl-CoA and acetyl-CoA units are then assembled into fatty 
acids by the fatty acid synthase (FAS). The liver and the adipose tissue are the two 
major sites of fatty acid synthesis in the body. During lactation, the mammary glands 
also synthesize large amounts of fatty acids. Acetyl-CoA is derived from break-down 
of glucose; therefore lipogenesis is very sensitive to blood sugar and insulin levels. 
Lipogenesis is stimulated when food is ingested and blood sugar/insulin levels increase. 
The SREBP isoform 1c is a key transcriptional activator of genes involved in 
lipogenesis (i.e. ACC and FAS). SREBP1c  is stimulated by insulin, but is also 
activated through LXR (section 1.2.1). High levels of free fatty acids are toxic to cells 
and the generated fatty acids are therefore rapidly esterified to glycerol, forming 
acylglycerols. The most common form is TAG which is either stored in lipid droplets 
within the cell or used for the assembly of very low-density lipoprotein (VLDL) 
particles that are released into the blood stream (see section 1.1.3). To utilize the energy 
bound within the fatty acid molecules, cells must first break down the molecules into 
acetyl-CoA. But, since acetyl-CoA is both substrate for lipogenesis and product of the 
oxidative break-down of fatty acids, these two reactions must be kept apart to ensure 
proper regulation. Therefore, β-oxidation of fatty acids takes place within the 
mitochondria. 
 
Mitochondrial β-oxidation of fatty acids generates acetyl-CoA. To produce ATP, 
acetyl-CoA must enter the citric acid cycle where it is consumed together with water, 
resulting in reduction of NAD+ to NADH and production of CO2. NADH is then used 
in the oxidative phosphorylation pathway (electron transfer chain) which ultimately 
results in the phosphorylation of ADP to ATP. All these steps occur inside the 
mitochondrion.  
 
Long-chain fatty acids (fatty acids with aliphatic tail of 14 carbons or longer) are 
activated by acyl-CoA synthetase (ACS) forming acyl-CoA, which enter the 
mitochondrion in three steps; (1) carnitine palmitoyltransferase (CPT) I conjugates 
acyl-CoA to carnitine, (2) the acyl-carnitine conjugate is transferred into the 
mitochondrion by a translocase and (3) carnitine and acyl-CoA is released by CPT II 
(figure 6). Malonyl-CoA regulates this first step of β-oxidation by inhibiting CPT 
activity. The medium- and short-chain fatty acids are able to diffuse into the 
mitochondria directly and are activated by acyl-CoA synthetases in the mitochondrial 
matrix.  
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Figure 6. An overview of the transport of long-chain fatty acids into the mitochondrion. OMM = outer 
mitochondrial membrane, IMM = inner mitochondrial membrane, FA = fatty acid, ACS = acyl-CoA 
synthetase, CPT = carnitine palmitoyltransferase.  
 
Inside the mitochondrion, acyl-CoA is repeatedly shortened by four reoccurring steps; 
(1) oxidation, (2) hydration, (3) oxidation and (4) thiolysis, yielding acetyl-CoA and 
acyl-CoA (two carbon atoms shorter in tail length compared to the initial acyl-CoA). 
This process continues until only acetyl-CoA remains (figure 7). 
 
 
 
Figure 7. An overview of mitochondrial β-oxidation.  
 
All of the enzymes involved in mitochondrial β-oxidation that are known today are 
products of genes encoded within the nuclear DNA. The mitochondrial genome, which 
is inherited maternally, consists of 37 genes which encode transfer (t)RNA, ribosomal 
(r)RNA and 13 peptides (proteins) involved in the oxidative phosphorylation system 
[19]. 
 
1.1.2.2 Intestinal fatty acid metabolism 
TAGs are the major components of the fat that enters the small intestine from dietary 
sources. Acid lipase activity in the stomach (also in the saliva of rodents) initiates the 
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degradation of TAGs, resulting in fatty acids and diacylglycerols. In duodenum, 
pancreatic lipase continues the hydrolysis to release more free fatty acids and 
monoacylglycerides (predominantly 2-monoacylglycerols) that can be absorbed by 
enterocytes. Pancreatic lipase can only function in the interface between water and 
lipids; therefore efficient intestinal uptake of fatty acids is dependent of emulsification 
of fats by bile acids and formation of micelles. Fatty acids can enter the enterocytes 
through passive diffusion and possibly also through transporter mediated uptake. The 
specific proteins involved in this process are however not identified. One protein, 
cluster of differentiation 36 (CD36) interacts with fatty acids in enterocytes of the 
proximal intestine, but elimination of CD36 does not affect net absorption of fatty acids 
[20-22]. Inside the enterocyte, fatty acids are re-joined with monoacylglycerol to form 
TAGs that are transferred into chylomicrons and excreted in the lymph (see section 
1.1.3) [23]. 
 
1.1.3 Transport of cholesterol and fatty acids by lipoproteins 
Cholesterol and TAG have very low solubility in water. Therefore, to enable transport 
of these substances in the blood stream, they are packed in molecular complexes called 
lipoproteins. Lipoproteins consist of a hydrophilic surface, containing proteins, free 
cholesterol and phospholipids, and a hydrophobic core, containing TAG and 
cholesteryl esters. Lipoproteins are commonly classified according to their size or 
density as chylomicrons, very low-density lipoprotein (VLDL), intermediate-density 
lipoprotein (IDL), low-density lipoprotein (LDL) and high-density lipoprotein (HDL), 
starting with the largest particle. Each class also contains several subclasses, in which 
the lipoproteins are grouped according to their protein and lipid content, and sometimes 
their shape. The proteins attached to the lipoprotein surface are called apolipoproteins 
and determine the faith of the lipoprotein particle by binding to different receptors 
located on cell surfaces or by activation of lipolytic enzymes. These receptors facilitate 
uptake of lipids or entire lipoprotein particles into the cell, or can administer lipids to 
the lipoprotein particle. Transportation of cholesterol and fatty acids in the blood stream 
can be divided into three main routes: the exogenous pathway, the endogenous pathway 
and reverse cholesterol transport.  
 
1.1.3.1 The exogenous pathway 
The exogenous pathway constitutes the transport of cholesterol and fatty acids from the 
brush-border membrane of the small intestine and out to peripheral tissues, ending with 
the uptake of chylomicron remnants by the liver. It starts with the uptake of dietary 
cholesterol and fatty acids in the intestine. Most of the retrieved cholesterol and fatty 
acids are re-esterified into cholesteryl esters and TAG, and transferred into 
chylomicrons. Chylomicrons are the largest and most short-lived lipoprotein particles, 
consisting mostly of TAG, but also carry cholesterol and phospholipids. They are 
secreted by the enterocytes into lymph vessels, to be released into the blood stream via 
the thoracic duct. Their main purpose is to deliver fatty acids to the white adipose 
tissue, muscles and the liver. The nascent chylomicron contains the apolipoprotein 
ApoB48, an edited shorter form of ApoB which cannot bind efficiently to the LDL-
receptor [24]. Upon release into the blood and interaction with HDL, chylomicrons 
acquire ApoCII and ApoE, necessary for efficient hydrolysis of triglycerides by 
lipoprotein lipase (LPL) and subsequent uptake of the free fatty acids into cells. After 
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delivering most of the triglycerides to the tissues, ApoCII is returned to HDL and the 
chylomicron remnants are taken up by the liver for breakdown. The uptake is 
dependent on functional ApoE for binding to the LDL-receptor and LDL-receptor 
related protein 1 (LRP1) [25-27]. In ApoE deficient mice, this last step fails and 
chylomicron remnants accumulate in the blood stream, making these genetically 
manipulated mice very sensitive to increased dietary cholesterol levels. Some of the 
cholesterol transported by chylomicrons can be taken up by peripheral tissues, but the 
major part is delivered to the liver.  
 
1.1.3.2 The endogenous pathway 
The endogenous pathway constitutes the transport of TAG and cholesterol from the 
liver in VLDL particles, for delivery to peripheral tissues, ending with the uptake of 
LDL by the liver. VLDL particles that are formed and secreted by the liver contain 
TAG, cholesterol, phospholipids and ApoB [28, 29]. ApoB secreted from human livers 
consists of the unedited full-length version; ApoB100, while mice secrete both 
ApoB100 and the edited form; ApoB48 [30-32]. Upon interaction with HDL, the 
VLDL particles acquire ApoCII and ApoE which facilitates the donation of fatty acids 
from VLDL to the tissues in the same way as for chylomicrons. In humans, VLDL 
donates TAG in exchange for cholesterol and phospholipids from HDL via the 
cholesteryl ester transfer protein (CETP). This step does not occur in mice, since mice 
are naturally devoid of CETP. As more and more TAGs are removed from the VLDL 
particles, they turn into IDL particles which still contain more than 50 % TAG, but no 
ApoCII. ApoCII is returned to HDL in circulation. IDL is either taken up by the liver 
by binding of ApoE to the LDL-receptor, or further relieved of TAG and ApoE turning 
into LDL. LDL particles contain low levels of TAG, high levels of cholesterol and 
phospholipids, and ApoB100. LDL delivers cholesterol to various organs by binding of 
ApoB to LDL-receptors on the cell surfaces. The complete LDL particle is endocytosed 
together with the LDL-receptor, of which the latter is re-circulated back to the cell 
surface [33, 34].  
 
1.1.3.3 The reverse cholesterol transport 
The reverse cholesterol transport constitutes the transport of cholesterol from peripheral 
tissues back to the liver for excretion in the bile, ending with the elimination of 
cholesterol from the body in the faeces. HDL particles are formed by secretion of 
ApoAI, mainly from the liver, which rapidly forms complexes with phospholipids and 
free cholesterol through interaction with the ATP-binding cassette (ABC) A1 protein 
expressed on cell surfaces. The liver is the major production site for HDL and hepatic 
ABCA1 is crucial for HDL synthesis and lipidation of ApoAI [35]. The HDL particle 
acquires more free cholesterol from peripheral tissues and cells, including 
macrophages, through interaction with ABCA1 and ABCG1 proteins expressed on cell 
surfaces. The acquired free cholesterol is esterified by Lecithin-cholesterol 
acyltransferase (LCAT) and stored in the HDL particle as cholesteryl esters. The 
accumulation of cholesteryl esters in HDL makes the particle increase in size and 
become spherical. HDL transports the acquired cholesterol to the liver where the 
scavenger receptor B1 (SR-B1) mediates uptake of cholesterol into the liver, but leaves 
the HDL particle in circulation. Excess ApoAI is metabolized in the kidneys. In the 
liver, cholesterol can be transferred to the bile as free cholesterol or bile acids for 
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subsequent elimination in the feces. HDL fractional catabolism and circulating levels 
are to some extent regulated by hepatic lipase (HL) and endothelial lipase (EL). 
Increased activity of HL or EL generally leads to reduced HDL levels and size, while 
defects in these lipases increase HDL [36]. Many apolipoproteins have been associated 
with HDL, but the major apolipoproteins in HDL are ApoAI and ApoAII [37, 38]. 
 
1.2 REGULATION OF LIPID HOMEOSTASIS BY NUCLEAR RECEPTORS 
This chapter contains descriptions of the nuclear receptors studied in this thesis. 
Nuclear receptors are proteins which are activated by specific ligands (molecules) and 
thereby control the transcriptional expression of genes. Today there are 48 and 49 
known nuclear receptors in humans and mice respectively, most of them are shared 
between these species [39]. We have studied the effects of oral administration of 
synthetic ligands for three of those receptors: the liver x receptor (LXR), the farnesoid x 
receptor (FXR) and the thyroid hormone receptor isoform β (TRβ). Upon activation, 
these receptors heterodimerize with the retinoid x receptor (RXR). 
 
1.2.1 The Liver x receptor  
The LXR subfamily consists of two members; LXRα (NR1H3) and LXRβ (NR1H2). 
LXRβ is ubiquitously expressed, while LXRα is mainly expressed in liver, adipose 
tissue, intestine, kidney and macrophages. These receptors regulate lipid metabolism 
and the importance of these receptors is evident in mice lacking LXR [40-42].  
 
Both LXR isoforms are considered to be stimulated by oxysterols; 22(R)-
hydroxycholesterol and 24(S), 25-epoxycholesterol [43, 44]. The relevance of these 
ligands for in vivo activation of LXR is however under debate since the ratio of 
oxysterols to cholesterol may be too low for LXR activation and direct proof of in vivo 
effects of increased oxysterol levels are missing [45].  
 
Synthetic ligands for LXR have been developed and tested in animals. T0901317, the 
first synthetic non-steroidal ligand for LXR, opened the door for more extensive studies 
on LXR regulation in vivo [46]. Systemic stimulation of LXR was found not only to 
modulate cholesterol homeostasis, but also to induce SREBP1c and lipogenesis in the 
liver, leading to hepatic steatosis. Thereafter the development of synthetic LXR 
agonists was aimed at finding substances that could induce the beneficial effects on 
cholesterol homeostasis without affecting hepatic lipogenesis. One strategy was to 
develop tissue specific agonists that stimulated LXR in the intestine more efficiently 
than in liver. GW3965 is one such compound [47, 48] and in recent years several other 
compounds have been identified and tested in animal studies. Synthetic LXR agonists 
have been shown to be anti-atherogenic by oral administration in mice with ApoE or 
LDL-receptor deficiency [49, 50].  
 
The anti-atherogenic properties of LXR agonists include increased HDL-cholesterol 
and RCT [51]. These effects are mediated through induction of genes involved in 
cholesterol transport; Abca1, Abcg1 and Abcg5/g8. The activation of these genes is 
believed to be protective against accumulation of cholesterol within the cells. In mice, 
LXRα regulates bile acid synthesis by inducing Cyp7a1, but this regulation does not 
exist in humans due to lack of homology in the DR-4 promoter element [52]. 
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Activation of LXR in CETP expressing animals (for example monkeys) is reported to 
increase LDL-cholesterol [53] and this poses an important obstacle to overcome for 
future development of LXR agonists intended for human use. 
 
1.2.2 The Farnesoid x receptor  
FXR (NR1H4) was originally identified as a receptor for farnesol, an intermediate in 
cholesterol synthesis, hence the name; farnesoid x receptor. FXR is a major regulator of 
bile acid synthesis in both humans and mice. Activation of FXR suppresses bile acid 
synthesis by reducing the expression of Cyp7a1 and Cyp8b1. This is however an 
indirect action; FXR does not bind directly to these genes, but induces transcription of 
small heterodimer partner (Shp). SHP interacts with the liver receptor homolog-1 
(LRH-1), and possibly also hepatocyte nuclear factor 4α (HNF4α), leading to inhibition 
of their transactivation of Cyp7a1 [54, 55].  
 
Bile acids are ligands to FXR and CDCA is considered to be the most potent [56-58]. 
However, CA seems to be an important mediator of FXR signaling in mice [9, 59]. The 
enterohepatic circulation of bile acids mediates FXR signaling between the intestine 
and liver; FXR is expressed in both organs. In the distal small intestine (ileum), uptake 
of bile acids activates FXR and induces expression of fibroblast growth factor 15 
(Fgf15) in mice [60] or Fgf19 in humans [61], which is secreted into the blood. This 
peptide activates FGF receptor isotype 4 (FGFR4) in the hepatocytes, which in turn 
suppresses Cyp7a1 and bile acid synthesis [60-62].  
 
The development of a non-steroidal FXR agonist, GW4064 [63], was an important step 
in identifying FXR regulated pathways since bile acids also exert effects apart from the 
FXR regulation. The effects of FXR deficiency on atherosclerosis have been 
investigated in both FXR-/-/ApoE-/- and FXR-/-/Ldlr-/- mice, but results from these 
studies have not given conclusive answers. The FXR-/-/ApoE-/- mice displayed 
increased or decreased atherosclerosis in males or females respectively, despite higher 
plasma levels of cholesterol in both genders after feeding with an atherogenic diet [64, 
65]. Male, but not female, FXR-/-/Ldlr-/- mice developed less atherosclerosis and had 
reduced plasma lipids compared to Ldlr-/- controls [66].  
 
Interestingly, the ApoaI gene is negatively regulated by FXR in both humans and mice; 
FXR activation reduces ApoaI expression by binding to a response element in the gene 
[67]. Many studies in both mice and humans suggest a negative relationship between 
bile acids/FXR and HDL where increased bile acid concentration or FXR activation 
reduces HDL and ApoAI. Treatment with bile acid sequestrants in humans or FXR 
deficiency in mice typically raises HDL, but it is uncertain whether this is due to 
increased ApoAI secretion and synthesis of HDL, or if it is a result of reduced uptake 
of cholesterol via hepatic SR-B1 [68]. Inhibition of FXR could thus mediate anti-
atherosclerotic actions through regulation of ApoaI. 
 
FXR is also expressed in vascular smooth muscle cells and endothelial cells where it 
may induce macrophage recruitment if stimulated [69, 70]. 
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1.2.3 Thyroid hormone and the thyroid hormone receptor 
The lipid-lowering effect of thyroid hormone (TH) administration is well documented 
and described. The thyroid hormones T4 and T3 are synthesized and secreted from the 
thyroid gland. T4 that has entered cells from the blood stream can be converted to T3 by 
deiodinases. T3 binds to the thyroid hormone receptors (TRs) in the nucleus of the cell 
and modulates the expression of genes involved in several metabolic pathways. The 
two TR isoforms α and β show different tissue specific expression and are encoded by 
different genes. TRα is involved in lipid metabolism in the heart, where stimulation 
increases the heart rate and cardiac output. TRβ mediates the effects of TH on hepatic 
cholesterol and bile acid synthesis by inducing bile acid synthesis and increasing LDL-
receptor expression [71]. Contrary to LXR, TRβ regulates Cyp7a1 expression in both 
humans and mice [72].  
 
To specifically induce the hepatic metabolism of cholesterol and thereby reduce plasma 
cholesterol, TRβ specific modulators have been developed. One such modulator; GC-1, 
has been shown to effectively reduce plasma lipids without cardiac effects in animal 
studies. GC-1 has also been shown to increase bile acid synthesis and hepatic SR-B1 
expression in normal and hypercholesterolemic mice [73]. Later, GC-1 was shown to 
reduce plasma cholesterol independently of the LDL-receptor by increasing hepatic bile 
acid synthesis and output in feces [74].  
 
Several other TRβ specific modulators have also been developed and tested in humans 
and animals. For example, KB141 was shown to reduce plasma cholesterol and induce 
bile acid synthesis without affecting the heart in mice, rats and primates [75] and 
KB2115 had the same effect in humans [76, 77]. The reduction of atherosclerosis 
development in ApoE deficient mice by combined treatment with the TRβ specific 
modulator KB3495 and atorvastatin was however independent of plasma cholesterol 
[78]. There are so far no TRβ modulators approved for human medicine. The phase III 
program for eprotirome (KB2115) was discontinued after negative side-effects of 
cartilage damage seen in dogs exposed to the substance for 12 months 
(www.karobio.com). 
 
1.3 LIPIDS IN DISEASE 
The high diversity of lipids in our bodies makes lipid homeostasis a complex business, 
therefore imbalance in this homeostasis can result in a wide range of symptoms and 
diseases. This chapter describes the role of cholesterol in atherosclerosis and how 
mtDNA depletion might affect mitochondrial β-oxidation of fatty acids.  
 
1.3.1 The role of cholesterol in atherosclerosis 
In 1916 it was observed that feeding rabbits with cholesterol rich diets gave rise to 
aortic lesions much similar to those observed in humans [79]. Before that it had been 
observed that aortic lesions in men contained crystallized cholesterol, but this was the 
first evidence that cholesterol uptake from the food directly influenced the development 
of atherosclerotic lesions. High levels of ApoB-containing lipoproteins (VLDL/LDL) 
or low levels of ApoAI-containing lipoproteins (HDL) as independent, causative risk 
factors for cardiovascular disease [80, 81]. Today atherosclerosis is known to be a 
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disease with an important inflammatory component, often induced by 
hypercholesterolemia. The immune response elicits both pro-atherogenic and anti-
atherogenic actions during the course of the disease [82, 83].  
 
The atherosclerotic lesion is a slowly developing, degenerative process which is non-
symptomatic until the size of the lesion or rupture blocks the artery and interrupts the 
flow of oxygenated blood, causing heart-attack or stroke. The retention and entrapment 
of LDL particles in the vascular wall is commonly accepted as the onset of 
atherosclerosis. High levels of plasma LDL mean more particles are available at the 
artery wall, increasing the risk of LDL entrapment. Studies have shown that the 
retention of LDL is dependent upon interaction of negatively charged proteoglycan 
sugars and certain positively charged domains of ApoB100 [84]. LDL particles trapped 
inside the vascular wall are more prone to oxidative damage [85]. Oxidized LDL 
stimulates the immune response and attracts monocytes that enter the artery wall. The 
monocytes differentiate into macrophages and when they become loaded with lipids, 
they turn into foam cells. The early stage atherosclerosis is defined as a fatty streak; the 
accumulation of lipids and foam cells in the artery wall. As the fatty streak develops 
into an advanced atherosclerotic lesion, a fibrous cap is formed over the plaque. Many 
different cell types are involved in the formation of an atherosclerotic plaque, but the 
most abundant ones are fibroblasts, smooth muscle cells, monocytes/macrophages and 
T-cells. 
 
It is believed that the major anti-atherogenic property of HDL is the cholesterol uptake 
from macrophages through interaction with ABCA1 and ABCG1. The engulfment of 
oxidized LDL by macrophages thus makes cholesterol in the arterial wall accessible for 
removal through RCT. HDL and ApoAI also function as anti-oxidants, reducing 
oxidized LDL. In recent years, several studies have suggested that the functionality of 
the HDL particles is important for effective clearance of macrophage cholesterol; 
smaller particles and increased particle number may be more efficient than fewer and 
larger particles. Also, the pro- or anti-inflammatory properties of HDL can enhance or 
reverse the progress of atherosclerosis. Therefore, high levels of HDL may not always 
be anti-atherogenic [86, 87].  
 
1.3.1.1 Atherosclerosis in ApoE deficient mice 
Mice carry the major part of their plasma cholesterol in HDL, contrary to humans who 
carry it in LDL. Due to this, and their lower plasma levels of total cholesterol in 
general, mice are very resistant to atherosclerosis. Mice must therefore be genetically 
manipulated to gain a more human-like lipoprotein profile and develop human-like 
atherosclerotic plaques to be used for medical research. Several mouse models for 
atherosclerosis have been developed over the years, including LDL-receptor deficient 
mice (Ldlr-/-), combined LDL-receptor and ApoE deficient mice (ApoE-/-/Ldlr-/-), 
combined ApoB100 transgenic and LDL-receptor deficient mice (ApoB100/Ldlr-/-) and 
mice transgenic for the human ApoE3 mutation (ApoE*3-Leiden). But, the earliest and 
most commonly used model for atherosclerosis is the ApoE deficient mouse developed 
by gene targeted homologous recombination in pluripotent stem cells, in two separate 
laboratories in the 1990´s [88, 89]. The morphology of lesions in these mice is 
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comparable to human lesions and they develop from fatty streaks into complex lesions. 
The ApoE deficient mice develop atherosclerosis spontaneously on chow diet, but the 
process is accelerated by increased dietary cholesterol [90].  
 
1.3.2 Defects in hepatic mitochondrial β-oxidation of fatty acids  
A genetic classification of mitochondrial diseases of oxidative metabolism 
distinguishes two principal categories: disorders caused by mutations in the mtDNA 
and disorders caused by mutations in nuclear DNA. Defects in the nuclear genes 
encoding enzymes involved in mitochondrial β-oxidation have been identified and the 
abnormalities in plasma acylcarnitines that they result in have been described [91]. 
Hepatic disorders of fatty acid oxidation are severe, often lethal, diseases in infancy 
or the neonatal period, which result in hypoglycaemia and lipid accumulation in 
tissues that normally do not store large amounts of lipids (i.e. liver, heart and skeletal 
muscle). Symptoms do, however, vary greatly among individuals.  
 
In humans, hepatic CPT deficiency is associated with delayed ketone body production 
(hypoketotic hypoglycemia) and dramatically increased long-chain acylcarnitines in 
serum after fasting. In mice, partial deficiency of the hepatic isoform CPT Ia 
(homozygous CPT Ia-/- is embryonic lethal) leads to reduced fasting serum glucose and 
increased free fatty acid levels [92]. The first oxidative step of long-chain fatty acid β-
oxidation in mice is carried out by long-chain acyl-CoA dehydrogenase (LCAD) and 
disruption of this step causes hypoglycemia, increased free fatty acids in plasma and 
accumulation of fat in heart and liver. LCAD deficient mice also become hypothermic 
with abnormal brown adipose tissue. A dehydrogenase for very long-chain acyl-CoA 
has also been discovered (VLCAD). VLCAD deficiency in mice does not result in any 
definite clinical phenotype at rest, but stress, fasting or cold exposure results in 
impaired running speed and distance, hypoglycemia, hypothermia and lethargy. 
Contrary to mice, in humans, VLCAD covers a great part of palmitoyl-CoA oxidation 
and LCAD is not as highly expressed. The medium- and short-chain acyl-CoA´s are 
oxidized by MCAD and SCAD respectively [93]. The condition caused by long-chain 
fatty acid oxidation disorders can however be prevented by dietary interventions 
including fatty acid restriction and glucose supplementation. Therefore fatty acid 
oxidation defects, such as VLCAD, LCAD and CPT deficiencies, are included in the 
neonatal screening program (PKU-test in Sweden).  
 
Mitochondrial (mt)DNA depletion syndromes (MDS) are severe autosomal recessive 
disorders that are characterized by quantitative reduction of mtDNA in affected tissues. 
Three classes of defective genes that cause MDS have been identified; (1) proteins that 
function directly at the mtDNA replication fork; polymerase gamma (POLG) and 
C10orf2/PEO1 (Twinkle), (2) enzymes involved in the salvage pathways of 
mitochondrial deoxynucleotides or in the control of the mitochondrial 
deoxynucleotide triphosphate pools; thymidine kinase 2 (TK2), deoxyguanosine kinase 
(DGUOK) and MpV17 mitochondrial inner membrane protein (MPV17) and (3) 
proteins influencing several steps of mitochondrial protein replication; elongation 
factors, aminoacyl-tRNA synthetases or mtDNA encoded tRNA. These disorders 
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affect the function and replication of the mitochondrial genome itself. Insufficient ATP 
production for cellular requirements, due to the involvement of mitochondrially 
transcribed peptides in oxidative phosphorylation, is thought to be the biochemical 
basis of the disease. Children with MDS are often born after a normal pregnancy, but 
symptoms present soon after birth and are often fatal after months or a few years of age 
[94]. Whereas reduced activity of DGUOK, POLG or MPV17 leads to hepatic failure 
and encephalomyopathy, mutations in TK2 have mostly been associated with severe 
myopathy [95-97]. However, the symptoms of humans harboring TK2 mutations vary 
depending on the degree of functional reduction; partial impairment seems to cause 
mainly myopathy, while severe impairment may also cause liver failure and 
encephalomyopathy [98, 99].  
 
Thymidine kinase isoforms 1 and 2 are enzymes encoded in the nuclear DNA. While 
TK1 is a cytosolic, cell-cycle dependent enzyme which is highly expressed in 
association with cell division, TK2 is found within the mitochondria and is cell-cycle 
independent. TK phosphorylates deoxythymidine to deoxythymidine monophosphate 
(dTMP), which provides dTMP for DNA replication; the process where DNA is 
copied. Down regulation of cytosolic TK1 and dNTP synthesis in non-dividing cells 
(tissues like muscle, liver and brain) forces mitochondrial TK2 (and DGUOK) to 
sustain the mitochondrial dNTP pool. In replicating tissues, the mitochondrial dNTP 
pool is maintained through cytosolic TK1 activity and influx of dNTP to the 
mitochondria via deoxyribonucleotide carrier (DNC) which bypasses the enzymatic 
step catalyzed by TK2. TK2 deficiency therefore leads to mitochondrial (mt)DNA 
depletion in non-replicating tissues [100] (figure 8). 
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Figure 8. TK1 and TK2 are transcribed from genes in the cell nucleus. TK1 is cytosolic, while TK2 is 
located within the mitochondria. TK2 deficiency in non-dividing cells with low TK1 expression leads to 
dNTP depletion and impaired mitochondrial DNA replication.  
 
1.3.2.1 The thymidine kinase deficient mouse model  
The initial characterization of TK2 deficient mice revealed that they were born 
indistinguishable from their wild-type litter mates and grew normally during the first 
week of life. MtDNA levels in skeletal muscle, heart, spleen and liver were normal at 
birth, while adipose tissue and brain showed mtDNA depletion already at birth. 
Histological analysis of tissues revealed distortion of muscle fibres and mitochondrial 
christaes in the heart. The hypodermal fat layer and the brown adipose tissue of TK2 
deficient mice did not develop normally and mice became increasingly hypothermic. 
Histological sections of adipose tissue showed heterogeneity in size and accumulation 
of lipid vesicles, and liver sections showed an increased number of lipid vesicles. The 
accumulated data suggested that the lipid metabolism was affected and perhaps 
involved in the disease progress [101]. The TK2 deficiency can be rescued by 
transgenic expression of drosophila melanogaster nucleoside kinase, which corrects the 
dTTP pool and mtDNA levels [102]. Some important species differences in TK2 
activity between humans and rats have been described; humans have high activity in 
liver and lower activity in muscle, while rats display low activity levels in both muscle 
and liver [103]. The markedly lower TK2 activity in rodent liver has been proposed to 
make rodents more susceptible to TK2 deficiency-induced liver failure, compared to 
humans. The severity of TK2 deficiency for the mouse brain has been demonstrated by 
Hirano et al [104, 105]. They created a TK2 (H126N) knock in mouse that displayed 
very similar symptoms and survival rate as the TK2 knock out mouse. Mouse models 
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for TK2 deficiency may thus be more feasible as models for infantile fatal 
encephalomyopathy, than as comparable models for human partial TK2 deficiency. 
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2 AIMS 
The aim of this thesis was to investigate and describe the regulation of hepatic and 
intestinal lipid metabolism, especially cholesterol metabolism and its relation to 
atherosclerotic development and the effect of mtDNA depletion on hepatic β-oxidation 
of fatty acids. 
 
The following questions were asked and answered: 
 
1. Does CA depletion reduce atherosclerosis development in ApoE deficient mice? 
 
2. Does oral administration of GC-1 reduce atherosclerosis development in ApoE 
deficient mice? 
 
3. Is the LXR driven increase in HDL-cholesterol dependent on intact intestinal 
cholesterol absorption? 
 
4. Does reduced intestinal cholesterol absorption and simultaneous LXR stimulation 
lead to synergistic effects on cholesterol metabolism that may inhibit atherosclerosis 
development? 
 
5. Does mtDNA depletion due to thymidine kinase 2 deficiency affect hepatic β-
oxidation in mice? 
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3 MATERIALS AND METHODS 
3.1 MICE 
All animal experiments were conducted in accordance with accepted standards for 
animal care and approved by the institutional Animal Care and Use Committee at 
Karolinska Institutet. 
 
In total 16 male ApoE(-/-)/Cyp8b1(-/-) (double knockout) and 24 male ApoE(-/-) mice, 
purchased through Taconic, Denmark, were used for paper I. 60 male ApoE -/- mice 
were used for paper II. 60 male C57Bl6 mice from our own in house breeding were 
used for paper III and 18 TK2(-/-) and 18 TK2(+/+) mice were used for paper IV. 
 
For paper I mice of both genotypes were fed either chow diet or an atherogenic diet 
containing 0.2 % cholesterol and 10 % peanut oil. Mice received these diets from 1 
week up to 5 months. Food and water was available ad libitum. Some mice received a 
single dose of radioactively labeled isotopes (14C-cholesterol and 3H-sitostanol) 
intragastrically and were housed individually in cages with grid floors for collection of 
feces during the last 24 hours of the experiment. All mice were fasted 4 hours prior to 
euthanisation with CO2. 
 
For paper II mice were fed a diet containing 0.2 % cholesterol and 10 % saturated fatty 
acids. 30 mice served as controls and the other 30 were treated with GC-1 
(approximately 0.12 mg/kg/day mixed in the diet). Food and water was available ad 
libitum. Diets were given during 1, 10 and 20 weeks. 20 mice were killed at each time 
point (10 controls and 10 treated). All mice were fasted 4 hours prior to euthanisation 
with CO2. 
 
For paper III mice were fed a diet containing 0.2 % (w/w) cholesterol and 10 % (w/w) 
peanut oil, with or without supplementation of 0.012 % (w/w) ezetimibe 
(approximately 13 mg/kg/day mixed in the diet). All mice were gavaged once daily 
with 0.5 % methyl cellulose in water, with or without the LXR agonist GW3965 (40 
mg/kg bw/day). The specified diets and treatments were given during 8 days. Food and 
water was available ad libitum. All mice received a single dose of radioactively labeled 
isotopes (14C-cholesterol and 3H-sitostanol) intragastrically and were housed 
individually in cages with grid floors for collection of feces during the last 24 hours of 
the experiment. All mice were fasted 4 hours prior to euthanisation with CO2. 
 
For paper IV suckling pups of seven to 14 days of age were used. The pups were 
housed with their mother until euthanisation with CO2. 
 
3.1.1 Genotyping of mice 
For genotyping of mice with disrupted Cyp8b1 or ApoE genes (and their wild-type 
counterparts) we collected 1-2 mm tail or ear biopsies. These were placed in direct PCR 
reagent (Viagen Biotech) supplemented with protein kinase K (Sigma-Aldrich) in room 
temperature or 37 °C water bath until complete lysis of the tissue. The reaction was 
stopped by incubation in 85 °C for 45 minutes, according to the manufacturer´s 
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protocol. PCR reactions were performed on crude lysates with primers for ApoE or 
Cyp8b1 respectively. 
 
Primers for mutant and wild-type ApoE alleles [106] 
T1685E06: GCC TAG CCG AGG GAG AGC CG 
T1685E07: TGT GAC TTG GGA GCT CTG CAG C 
T1685E08: GCC GCC CCG ACT GCA TCT 
 
Primers for mutant and wild-type Cyp8b1 alleles [107] 
TCH-F2: AAA CCA CAC TGC TCG ACC TGC 
CMN antisence: TGA GCT GAC CAC ATG TGT TCC 
WTCH-F: CTT CCT CTA TCG CCT GAA GCC 
 
Genomic DNA purification of ear biopsies from mice with disrupted Tk2 gene (and 
their wild-type counterparts) was performed with the DNeasy Blood & Tissue kit 
(Qiagen) according to the manufacturer´s protocol. 
 
Primers for the mutant Tk2 allele [101] 
Tk2 F1: TAG TAG TTT AGA TGC CTG AGA CT 
Tk2 R: GCC AGC TCA TTC CTC CCA CTC 
 
3.2 QUANTIFICATION OF LIPIDS 
3.2.1 Plasma lipids 
For paper I-IV, size exclusion chromatography of plasma lipoproteins was performed 
as described earlier [108] and their lipid content was measured online with cholesterol 
CHOD-PAP and TG GPO-PAP reagents (Roche). 
 
For paper IV, serum non-esterified fatty acid (NEFA) concentration was determined by 
an enzymatic assay and plasma acyl-carnitine metabolites were quantitated by an LC-
MS/MS assay, as described in the article. 
 
3.2.2 Extraction of lipids 
For paper I-IV, total lipids were extracted with chloroform/methanol (2:1, by vol.) 
from serum and tissue samples using the method described by Folch et al [109]. 
Hydrolysis of sterol esters was performed by addition of KOH and ethanol to 
samples. Campesterol, free and total cholesterol, lathosterol and C4 were quantified 
by isotope dilution mass spectrometry [110-112]. Total cholesterol and triglycerides 
were also measured with the enzymatic cholesterol CHOD-PAP and triglycerides 
GPO-PAP reagents (Roche), using an Infinite F500 plate reader (Tecan) for detection. 
For this purpose, tritonX-100 was added to parts of extracts, the organic solvents 
were evaporated and lipids were solubilised in water. The remaining pieces of tissue 
after lipid extraction were dissolved in 1 M NaOH for protein determination by Bio-
Rad DC assay (BioRad Laboratories). All lipids are related to the amount of protein 
in the extracted tissue.  
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3.2.3 Quantification of neutral sterols and bile acids in feces 
For paper III, mice were placed in individual cages with grid floors for collection of 
feces during a 24-hour period. Fecal samples from each cage were analysed 
individually. For paper II, mice were housed together and fecal samples were 
collected cage-wise and analysed as pooled samples from the treatment groups. Feces 
were collected during two consecutive 24-hour periods. Homogenised and dried 
samples were weighed (~20 mg of pulverised faeces per sample) and hydrolysed by 
KOH in ethanol (120 °C) before extraction with hexane for neutral sterols. The 
extraction was repeated three times with 20 mL of hexane. Samples were then 
acidified with HCl and extracted for bile acids with 50 mL of dietylether. The 
extractions were performed in duplicate for all samples; d4-deoxycholic acid (DCA) 
and d4-lathosterol was added to one of the duplicates before hydrolysis, and the other 
was prepared without internal standards. All neutral sterol samples were 
trimethylsialylated prior to analysis and all bile acid samples were methylated with 
diazomethane and trimethylsialylated prior to analysis. Samples were quantitated in a 
similar manner as described in [113]. Amounts of DCA and lathosterol were 
quantified by isotope dilution mass spectrometry in samples containing internal 
standards. The other neutral sterols and bile acids were quantitated from the 
chromatogram (total ion current) of samples without added internal standard. Neutral 
sterols include: coprostanol, cholesterol, lathosterol, campesterol, stigmasterol, 
sitosterol and sitostanol and bile acids include: deoxycholic acid, chenodeoxycholic 
acid, cholic acid, α-, β- and ω-muricholic acid.  
 
For paper III, total cholesterol content of selected fecal samples were also determined 
using the cholesterol CHOD-PAP reagent after extraction of total lipids as described 
in section 3.2.1.  
 
For paper II neutral sterol content in the fecal samples was also determined by gas 
chromatography, using 5α-cholestane as an internal standard. Total bile acid 
concentration in the remaining water phase after hexane extraction was also 
determined with the enzymatic Total Bile Acids Assay (Diazyme Labs USA). 
 
3.2.4 Fractional intestinal cholesterol absorption 
In paper I and III we quantitated the fractional intestinal cholesterol absorption using 
the method described by Schwarz et al [114]. Mice were gavaged intragastrically with 
a single dose of 100 µL peanut oil containing 1 µCi 14C-cholesterol and 2 µCi 3H-
sitostanol and were then immediately transferred to individual cages with grid floor. 
Feces were collected during 24 hours. The collected fecal samples were homogenized 
in water and parts of the homogenates were extracted for lipids in chloroform/methanol 
(2:1, by vol.) according to Folch et al [109]. The extracts were transferred to 
scintillation vials, dried down under N2 and added 10 mL of Ultima Gold. Beta 
radiation was counted by a liquid scintillation counter. The per cent cholesterol 
absorption was calculated as:  
 
Cholesterol abs (%) = (gavage (14C/3H) – fecal sample (14C/3H))/ gavage (14C/3H).  
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Methodological limitations may give negative values after calculation; such values 
were set to 0 in all results presented within this thesis. 
 
3.3 GENE EXPRESSION (REAL-TIME PCR) 
For paper I-IV, total RNA was isolated from frozen liver tissue, scraped intestinal 
mucosa or cultured cells by homogenization in TRIzol (Life Technologies), 
subsequent steps were performed according to the manufacturer´s protocol. cDNA 
synthesis was carried out on 1 µg of total RNA using the High Capacity Reverse 
Transcriptase Kit (Applied Biosystems). In paper I and II cDNA samples from each 
treatment or genotype group were pooled by addition of equal amounts of cDNA 
from each individual. For measurements of mRNA levels, Power SYBR green PCR 
Master Mix (Applied Biosystems) was used with primers overlapping exon-exon 
boundaries. For detection Applied Biosystems PRISM 7500 Fast Real-time PCR 
System (Applied Biosystems) was used. The mRNA levels were related to the 
expression of mouse hypoxanthine phosphoribosyl transferase (Hprt) or Cyclophilin. 
All reactions were performed in triplicate and relative quantification was performed 
according to the comparative Ct-method (2-ΔΔCt)  [115]. 
 
For paper I, expressions of 45 selected genes involved in lipid metabolism were 
evaluated using a Low-Density TaqMan Array (LDA) (Applied Biosystems). Pooled 
cDNA samples were used for this purpose. 
 
3.4 PROTEIN EXPRESSION  
3.4.1 Immunohistochemistry 
For paper I, the amount of T-cells and macrophages in atherosclerotic plaques were 
determined by immunohistochemistry. CD3+ and I-A+ (T-cells) cell numbers and 
CD68 and CD106 (macrophages) stained area/plaque area was determined as described 
in the article. 
 
3.4.2 Sample preparation for western blot 
For paper III, samples were homogenized in a buffer containing 20 mM Tris, 2 mM 
MgCl2, 0.25 M sucrose and 1 % TritonX-100 for whole cell protein extraction. Samples 
were spun at 2000xg and the supernatant was collected.  
 
For paper II and III, hepatic cell membrane fractions were prepared by tissue 
homogenization in a buffer containing 20 mM Tris, 2 mM MgCl2, 0.25 M sucrose and 
protease inhibitor cocktail. After centrifugation 2000 xg, the supernatant was collected 
and centrifuged at 110,000 xg for 45 minutes. The supernatant was removed and the 
pellet was dissolved in 100 µL ice-cold buffer containing 80 mM NaCl, 50 mM Tris-
HCl (pH 8), 2 mM CaCl2, 1 % TritonX-100 and cOmplete Mini EDTA-free protease 
inhibitor cocktail (one tablet per 10 mL). A short centrifugation at 2000xg removed 
excess, undissolved material. 
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The total amount of protein in individual samples was determined by the Bio-rad DC 
assay (BioRad Laboratories) and equal amounts of total protein from each sample was 
added to make pooled samples. 
 
For paper IV, total protein from liver tissue was prepared as described in the article. 
  
3.4.3 Western blot 
For paper III, analysis of ApoAI in individual serum samples was performed by mixing 
1.5 µL of serum with NuPAGE LDS sample buffer (Life Technologies). Samples were 
then separated by SDS-PAGE.  
 
Prepared samples from tissue (whole cell extracts or cell membrane fractions) were 
mixed with NuPAGE LDS sample buffer (Invitrogen) + 0. 1 M dithiotreitol (DTT) for 
separation on NuPAGE Bis-Tris gels (Invitrogen) or were mixed with Laemmli sample 
buffer (Bio-Rad Laboratories) + 0. 1 M dithiotreitol for separation on NuPAGE Tris-
Acetate gels (Invitrogen). Proteins were transferred to nitrocellulose membranes and 
incubated with antibodies towards the LDL-receptor (Abcam), SR-B1 (Abcam), 
ABCA1 (Abcam), ABCG5 (a gift from Dr. Liqing Yu, Wake Forrest University [116]) 
or NPC1L1 (Novus Biologicals). All blots were incubated with respective secondary 
HRP-conjugated antibodies and after incubation with Super Signal West Dura 
Extended Duration Substrate (Pierce Biotechnology) the chemiluminescence intensity 
was detected in a Molecular Imager Gel Doc XR (Bio-Rad Laboratories). Densitometry 
analysis (rectangular volumes with global background subtraction) was performed with 
the Quantity One software (Bio-Rad Laboratories).  
 
For paper III, the relative protein expression in whole cell homogenate was normalized 
against β-actin and related to the vehicle sample.  
 
For paper II and III, the relative protein expressions in cell membrane fractions were 
determined by loading three amounts of each pool on the gel and calculating the ratio 
between ktreated and kvehicle/control (y=kx+m; y = chemiluminescence intensity, x = amount of 
total protein (mg)) for each treated sample.  
 
For paper IV, the relative protein expression was determined as described in the article. 
 
3.5 HEPATIC ENZYME ACTIVITIES 
3.5.1 Acyl-CoA:cholesterol acyltransferase (ACAT) 2 activity 
For paper I, microsomes were prepared and ACAT activity was determined according 
to Parini et al [4]. Frozen liver tissue was homogenized in a solution containing 0.25 M 
sucrose, 0.1 M K2HPO4, 1 mM EDTA (pH 7.4) and protease inhibitor cocktail. After 
centrifugation 13,000 xg for 15 minutes, the supernatant was collected and centrifuged 
at 150,000 xg for 30 minutes. The pellet was dissolved in 300 µL 0.1 M K2HPO4 and 
the total protein concentration was determined by the Bio-rad DC assay (BioRad 
Laboratories). The microsomes were saturated with exogenous cholesterol complexed 
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to β-cyclodextrin and BSA for 15 minutes. The reaction was started by addition of 14C-
oleoyl-CoA and stopped after 20 minutes by addition of chloroform/methanol (2:1, by 
vol.). Samples were run in duplicates, where one duplicate contained pyripyropene A 
(PPPA), a specific ACAT2 inhibitor, to discriminate between ACAT1 and ACAT2 
activity. 3H-cholesteryl oleate was added as an internal control. The organic phase was 
evaporated and cholesteryl esters were separated from other lipids by thin layer 
chromatography (TLC) and the radioactivity was determined by mixing the scraped 
sample with Ultima Gold scintillation liquid and counting the activity in a beta-counter. 
ACAT2 activity was calculated by subtraction of ACAT1 activity from the total ACAT 
activity. 
 
3.5.2 Mitochondrial β-oxidation 
For paper IV, the mitochondrial β-oxidation of palmitic acid was determined in isolated 
hepatic mitochondria from TK2-/- and TK2+/+ mice as described [117]. 
 
3.5.3 ATP production rate and citrate synthase activity 
For paper IV, the mitochondrial ATP production rates and citrate synthase activities 
were determined in isolated hepatic mitochondria from TK2-/- and TK2+/+ mice as 
described [118]. 
 
3.5.4 Carnitine palmitoyl transferase (CPT) activity 
For paper IV, the mitochondrial CPT activity was determined in isolated hepatic 
mitochondria from TK2-/- and TK2+/+ mice as described [119]. This method determines 
the total CPT activity, including CPT I and II. 
 
3.6 CELL EXPERIMENTS 
3.6.1 Primary mouse hepatocytes 
Primary hepatocytes from two adult female C57Bl6 mice (Charles River) were isolated 
and seeded on 12-well plates coated with collagen (700,000-750,000 cells/well) 
according to [120] at the centre for transplantation surgery, CLINTEC. 
 
3.6.2 HEPA1-6 cells 
HEPA1-6 cells (ATCC, US) stored in liquid nitrogen were quickly defrosted in 37 °C 
water bath and centrifuged to remove the medium. Cells were then re-suspended in 37 
°C DMEM High glucose medium (Life Technologies) with added heat-inactivated FBS 
(10 %) and Penicillin-Streptomycin (1 %). Cells were grown in cell culture flasks (75 
cm2) and were split twice (1/10) before experiments started, approximately one week 
and a half after thawing. 
 
3.6.3 Protocol for treatment of cells with GW3965 
Isolated primary hepatocytes were allowed to attach for 24 hours after seeding onto 12- 
well plates. Then, the medium was removed and 0.5 mL of medium containing either 
0.1 % DMSO (control), 0.1 %DMSO + 1 µM GW3965 or 0.1 %DMSO + 10 µM 
GW3965 was added to four of the 12 wells on each plate. Plates were then left in the 
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incubator for 48 hours in 5 % CO2, 37 °C. After 48 hours of treatment, the medium was 
removed and TRIzol (Life Technologies) was added to each well for RNA extraction. 
The TRIzol/cell mixture from each treatment group on one plate was pooled (four 
wells/pool) and RNA was isolated according to the manufacturer´s protocol. 
 
HEPA1-6 cells were seeded on 6-well plates by diluting cells from a 75 cm2 flask 
(approx. 90 % confluency) 1:3, adding 2 mL cell-suspension per well and allowing 
cells to attach for 24 hours before treatment. After 24 hours, three wells per plate were 
treated either with 0.1 % DMSO (control), 0.1 %DMSO + 1 µM GW3965 or 0.1 
%DMSO + 10 µM GW3965 for 24, 48 or 96 hours. The medium was then removed 
and TRIzol (Life Technologies) was added to each well for RNA extraction. RNA was 
extracted separately from each well according to the manufacturer´s protocol. 
 
3.7 STATISTICAL EVALUATION OF RESULTS 
For paper I, III and IV parametric tests were performed using the STATISTICA 
software. Data is presented as mean ± SEM. Some data was log-transformed prior to 
statistical analysis to meet the criteria of homoscedasticity in parametric tests. For paper 
II non-parametric tests were performed using the PRISM software. Results are 
presented as individual data points with median. P ≤ 0.05 was considered statistically 
significant in all tests. 
 
Paper I:  Figure 1 and table 1: the significance of difference was tested by student´s t-
test. For the main experiment, where DKO and ApoE KO mice were fed chow or 
cholesterol diet for two weeks or cholesterol diet for five months, the significance of 
difference was tested by two-way ANOVA (factors: genotype (DKO or ApoE KO) and 
diet (chow diet 2W, cholesterol diet 2W or cholesterol diet 5M)) followed by post hoc 
comparison by the LSD test whenever significant main effects or interaction of factors 
were detected. For the additional experiment with GW4064 and CA supplementation, 
the significance of difference was tested by one-way ANOVA followed by post hoc 
comparison by the LSD test. 
 
Paper II: Statistical significance of difference between groups for cholesterol levels in 
aortas was tested by one-tailed Mann-Whitney U-test (GC-1 treated expected to be 
lower than control). All other parameters were tested by two-tailed Mann-Whitney U-
test for statistically significant differences between control and GC-1 treated samples. 
All tests were performed between GC-1 and control samples within the same treatment 
period. Statistical analysis was not performed on fecal excretion of sterols, hepatic 
protein expression or plasma C4 measurements, because measurements were performed 
on pooled material. 
 
Paper III: The statistical significance of differences was tested by two-way ANOVA 
(factors: GW3965 and ezetimibe), followed by post-hoc comparison according to 
Dunnette´s test for comparison against the vehicle group. For figure 4c-d we used 
one-way ANOVA (factor: treatment), followed by post-hoc comparison according to 
Dunnette´s test for comparison against control treated cells. Post-hoc comparison was 
performed only when the ANOVA showed significant main effect(s) or interaction of 
factors (p≤0.05). For figure 1c, we used Spearman´s rank correlation to test for 
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correlation between the two parameters. For levels of ApoAI in serum, which were 
only comparable to vehicle samples on the same blot, we used two-tailed, unpaired t-
test.  
 
Paper IV: Two tailed, unpaired Student’s t-test was used to test for statistical 
significance of difference between TK2+/+ and TK2-/- mice of the same age. 
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4 RESULTS 
 
4.1 PAPER I: CA DEPLETION REDUCES ATHEROSCLEROSIS IN APOE 
DEFICIENT MICE 
 
In this paper we investigated the effect of CA depletion on atherosclerosis in ApoE 
deficient mice. Mice of ApoE-/-/Cyp8b1-/- genotype (double knockout = DKO) were 
compared to ApoE-/-/Cyp8b1+/+ (ApoE KO) mice. Mice were fed chow diet or an 
atherogenic diet containing 0.2 % cholesterol and peanut oil for 2 weeks or 5 months. 
An additional experiment where mice on chow diet were treated with the FXR agonist 
GW4064 or CA supplementation was performed to test whether FXR stimulation in 
CA depleted mice could restore intestinal cholesterol absorption and to discriminate 
between effects of FXR stimulation and CA depletion on gene expression and bile 
composition. 
 
CA depletion resulted in an approximate 50 % reduction of plaque area, as determined 
by oil Red-O staining, in aortas of the DKO mice after five months on the 0.2 % 
cholesterol diet. Mean plasma levels of cholesterol, mainly the cholesteryl esters, were 
lower in DKO mice compared to ApoE KO mice independently of the dietary regimen. 
The greatest difference occurred after feeding of the cholesterol diet for five months. 
The DKO mice fed either chow or 0.2 % cholesterol for two weeks displayed a 50-60 
% reduction in the fractional intestinal cholesterol absorption compared to ApoE KO 
mice. The main fractions of bile acids in the ApoE KO mice on chow or cholesterol 
diet were CA and β-MCA. As expected, disruption of Cyp8b1 resulted in complete 
abolishment of CA in the bile of the DKO mice. Increased levels of CDCA/α-MCA and 
β-MCA were detected in the bile of the DKO mice. The hepatic C4 content and Cyp7a1 
mRNA levels were increased in DKO mice, indicating increased bile acid synthesis as 
a result of CA depletion and loss of FXR suppression. The hepatic cholesteryl ester 
content and ACAT2 activity was reduced, while the cholesterol synthesis was 
increased.   
 
Oral administration of the synthetic FXR agonist GW4064 did not significantly affect 
bile composition or restore the cholesterol absorption in DKO mice, while oral 
supplementation with CA completely restored both bile composition and the 
cholesterol absorption. CA depletion or GW4064 treatment did not affect the intestinal 
gene expression for Npc1l1, Abcg5 and g8, indicating that the effect of CA depletion on 
intestinal cholesterol absorption was mediated mainly by reduced micellar 
solubilisation of cholesterol and not by transcriptional effects on cholesterol 
transporters. 
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4.2 PAPER II: GC-1 REDUCES ATHEROSCLEROSIS IN APOE 
DEFICIENT MICE 
 
In this paper, we investigated the effect of synthetic TRβ modulation on atherosclerosis 
in ApoE deficient mice. Mice were fed an atherogenic diet, containing 0.2 % 
cholesterol, supplemented with GC-1 for one, ten or 20 weeks. Control mice received 
the atherogenic diet without GC-1.  
 
GC-1 reduced atherosclerosis in aortas of ApoE deficient mice after 20 weeks of 
treatment. Surprisingly, serum cholesterol levels were reduced by GC-1 after one or ten 
weeks treatment, but not after 20 weeks, despite a prominent induction of hepatic LDL-
receptor protein expression. Hepatic SR-B1 expression was lower in GC-1 treated mice 
compared to control. Plasma levels of triglycerides or cholesterol in the HDL fraction 
could not be evaluated due to the high levels of ApoB-containing lipoproteins. GC-1 
increased the C4 concentration in liver tissue and serum independently of treatment 
time and resulted in significantly increased Cyp7a1 expression after ten weeks of 
treatment, indicating increased bile acid synthesis. Hepatic cholesterol synthesis was 
unaffected, but GC-1 treatment reduced hepatic cholesteryl esters after one week. 
Analysis of fecal samples revealed that GC-1 increased the neutral sterol content after 
one week treatment and the bile acid content after 20 weeks of treatment. The increased 
fecal neutral sterol content after one week treatment was paralleled by reduced serum 
levels of campesterol, indicating decreased intestinal cholesterol absorption.  
 
The results from this study show that GC-1 reduced atherosclerosis in ApoE deficient 
mice by multiple effects on cholesterol metabolism. The lipid-lowering effect of oral 
treatment with GC-1 was however transient. 
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4.3 PAPER III: THE LXR DRIVEN INCREASE OF HDL-C IS 
INDEPENDENT OF INTESTINAL CHOLESTEROL ABSORPTION 
 
In this paper, we investigated whether the LXR driven increase of HDL-cholesterol was 
dependent on intestinal cholesterol absorption and if combined LXR stimulation and 
blocked cholesterol absorption would lead to synergistic anti-atherogenic effects on 
cholesterol metabolism. We treated mice on a 0.2 % cholesterol diet with the LXR 
agonist GW3965, the cholesterol absorption inhibitor ezetimibe or a combination of 
both (GW3965+ezetimibe) for eight days. 
 
The combined treatment with GW3965 and ezetimibe resulted in increased HDL-
cholesterol, increased ApoAI levels in serum and reduced intestinal cholesterol 
absorption, but did not increase intestinal or hepatic ABCA1 protein expression. 
Hepatic SR-B1 expression in cellular membrane fractions were unaltered, indicating 
that the SR-B1 mediated uptake of HDL-cholesterol was not affected. Hepatic ApoaI 
mRNA levels were increased in mice treated with GW3965 or the combination of 
GW3965+ezetimibe.  
 
An additional experiment was performed where primary hepatocytes from mice and the 
hepatoma cell line HEPA1-6 were treated with GW3965 to elucidate whether hepatic 
ApoaI expression was stimulated directly by the LXR agonist. Results from this 
experiment showed increased ApoaI expression in hepatocytes and HEPA1-6 cells after 
treatment with 10 µM GW3965 in the cell medium for 48 hours or longer, confirming 
that GW3965 could stimulate ApoAI production in hepatocytes. Thus, the LXR driven 
increase of HDL-cholesterol was found to be independent of the intestinal cholesterol 
absorption and did not require increased ABCA1 expression. Increased hepatic ApoAI 
secretion may represent an anti-atherogenic property of GW3965 which was 
independent of intestinal cholesterol absorption. We proposed a mechanism were 
“base-line” expression of ABCA1 is sufficient to lipidate increased ApoAI levels in 
plasma as part of the LXR driven increase of HDL-cholesterol. 
 
We also compared the effect of ezetimibe or GW3965 treatment on intestinal 
cholesterol absorption, cholesterol content and transporters (Npc1l1, Abcg5 and Abca1). 
We found that ezetimibe treatment lowered Abcg5 and Abca1 mRNA and protein, 
while Npc1l1was unaffected. GW3965 treatment increased Abcg5 and Abca1 mRNA 
and protein and lowered Npc1l1 mRNA, as expected, but did not affect the intestinal 
cholesterol absorption or cholesterol content. However, neither ezetimibe nor GW3965 
reduced NPC1L1 protein expression, despite the transcriptional down regulation by 
GW3965. Interestingly, in mice treated with the combination of GW3965+ezetimibe, 
the intestinal cholesterol absorption and cholesterol content was reduced (resembling 
ezetimibe treatment). Transcriptional regulation of Npc1l1, Abcg5 and Abca1 was 
comparable to the effect of GW3965 treatment, but ABCG5 and ABCA1 protein 
expressions were unaffected compared to vehicle treated mice. Unexpectedly, NPC1L1 
protein expression was prominently reduced by the GW3965+ezetimibe treatment. 
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These results show that GW3965 did not reduce the intestinal cholesterol absorption, 
but also indicate that inhibited influx of cholesterol via NPC1L1 and/or low levels of 
intracellular cholesterol prevented post-transcriptional increase of intestinal ABCA1 
and ABCG5, despite increased mRNA levels.  
 
GW3965+ezetimibe treatment effectively increased fecal neutral sterol excretion and 
reduced hepatic cholesteryl esters; two anti-atherogenic properties of combined LXR 
activation and reduced intestinal cholesterol absorption. 
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4.4 PAPER IV: TK2 DEFICIENCY REDUCES HEPATIC MITOCHONDRIAL 
Β-OXIDATION  
 
In this paper we investigated whether the TK2 deficiency-induced mtDNA depletion in 
mice leads to defects in hepatic mitochondrial β-oxidation. We collected tissues from 
seven days (non-symptomatic), 12 and 14 days (symptomatic) old TK2 deficient mice. 
Their wild-type litter mates served as controls.  
 
Transmission electron microscopy of liver sections from TK2 deficient mice showed 
increasingly hypertrophic mitochondria with increasing age. The hepatic protein 
expression of cytochrome oxidase subunit II (COXII), a mitochondrial protein involved 
in the electron transfer chain, was however unchanged. Hepatic adipophilin, a protein 
associated with lipid vesicles, was increased in 12 days old TK2-/- mice, but 
paradoxically, hepatic cholesteryl esters and triglycerides were increased in seven days 
old mice, but not in the older mice. Serum cholesterol and free fatty acids were 
increased in the 12 days old TK2 deficient mice, while triglycerides were unchanged. 
Analysis of plasma acylcarnitine metabolites revealed that long-chain acylcarnitines 
were elevated, indicating dysfunction in the primary steps of transfer or oxidation of 
long-chain fatty acids in mitochondria. Analysis of the palmitate oxidation rate and 
CPT activity in isolated hepatic mitochondria from 14 days old TK2 deficient mice 
revealed that both parameters were reduced. Despite mtDNA depletion in hepatic tissue 
at post-natal day 14, no significant differences were detected in the mitochondrial ATP 
production rates between TK2 deficient and control mice.  
 
The results from this study show involvement of hepatic β-oxidation of long-chain fatty 
acids in the disease progress of TK2 deficient mice. 
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5 DISCUSSION AND COMMENTS 
 
Paper I-III 
 
Dyslipidemia is one major determinant of the pathogenesis of atherosclerosis, as well 
as overall mortality and morbidity in cardiovascular diseases (CVDs) [121, 122]. In 
paper I-III we tested different strategies to modulate plasma lipoproteins in ways that 
are considered to be anti-atherogenic. The ApoE deficient mouse model was used for 
paper I and II to elucidate whether the applied strategies would also reduce 
atherosclerosis. In both papers we employed strategies that were aimed at reducing 
ApoB-containing lipoproteins. In paper III we instead aimed at increasing ApoAI-
containing lipoproteins in wild-type mice.  
 
In paper I we showed that disruption of Cyp8b1 had profound effect on plasma 
cholesterol levels and atherosclerosis development in ApoE deficient mice. The lipid-
lowering effect of CA depletion was prominent and to this date no negative side-effects 
on survival, breeding or behavior have been observed in CA depleted mice. 
Development of inhibitors directed at CYP8B1 could therefore be a realistic alternative 
for future drug development. CA supplementation in humans has been reported to 
increase cholesterol absorption and bile content of CA [123], but the effect of CA 
depletion is not well documented in humans. So far, no polymorphism in the human 
Cyp8b1 gene has been associated with any disease [124]. The loss of FXR repression in 
CA depleted mice leads to increased bile acid synthesis and an expanded pool of bile, 
but the increased bile pool size did not compensate for the loss of CA in terms of 
intestinal cholesterol absorption. In fact, the reduced hydrophobicity of the bile acid 
pool in the DKO mice may also have contributed to the reduced absorption. We also 
showed that stimulation of FXR with a synthetic agonist did not restore the fractional 
intestinal cholesterol absorption in mice devoid of CA, meaning that the micellar 
composition and solubilization of cholesterol in the intestinal lumen is prior to FXR 
signaling for this parameter. Since CDCA is more potent as an FXR agonist in humans, 
and FXR does not regulate CYP7A1 and bile acid synthesis in humans in the same way 
as in mice, separation of the effect on intestinal cholesterol absorption from FXR 
signaling was important to demonstrate that the loss of CA is likely to reduce 
atherosclerosis and plasma lipids even when the FXR suppressive effect is lost.  
 
In paper II we tested if oral administration of GC-1 would decrease atherosclerosis in 
ApoE deficient mice. Our results showed that the sustained, increased hepatic LDL-
receptor expression observed after 20 weeks of oral GC-1 treatment was not enough to 
maintain reduced serum cholesterol levels in ApoE deficient mice, supporting the view 
of an LDL-receptor independent mechanism. Since LDL and VLDL levels are closely 
connected, it is not farfetched to think that hepatic VLDL secretion may be part of this 
mechanism. Secretion of TAG and cholesterol in VLDL is reduced in hyperthyroid rats 
[125], but the relationship between thyroid hormone and VLDL secretion is yet not 
clearly demonstrated since hypothyroidism may also decrease VLDL secretion [126]. 
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An initial reduction in intestinal cholesterol absorption may also in part explain the 
reduced serum cholesterol levels after short-term treatment. We detected reduced levels 
of serum campesterol in mice treated with GC-1 for one week, but previous work by 
Davidson et al showed that synthesis rates of ApoB48 were increased in hyperthyroid 
rats [126], indicating that intestinal chylomicron production was increased. It should 
also be pointed out that observations on fecal excretion of neutral sterols and bile acids 
after GC-1 treatment have differed among labs. We detected increased fecal excretion 
of neutral sterols after one week treatment with GC-1 administered intraperitoneally or 
orally (see [73] and the present study), but others have instead detected a prominent 
increase in fecal bile acid content and no increase in fecal neutral sterols [74]. The 
definitive effect of GC-1 on hepatic VLDL secretion and intestinal cholesterol 
absorption thus remains to be clarified. Interestingly, GC-1 treatment for 20 weeks 
reduced atherosclerosis, but not serum cholesterol levels. These results demonstrate two 
things; (1) the reduction of serum cholesterol after treatment with GC-1 is transient and 
(2) the reduced atherosclerosis is either independent of serum cholesterol levels or 
represents a postponement of disease onset due to short-term treatment effects.  
 
In paper III we tested whether increased HDL-cholesterol levels due to LXR 
stimulation were dependent on intestinal cholesterol absorption. Previous work by Tang 
et al suggested that the LXR driven increase in HDL-cholesterol might depend on 
intestinal cholesterol absorption [127]. However, our results clearly showed that the 
increase in HDL-cholesterol seen after LXR activation by GW3965 was not dependent 
on intestinal cholesterol absorption. In line with our results, it was recently reported that 
intestine-specific deletion of the Microsomal triglyceride transfer protein (Mttp) 
resulted in inhibited intestinal cholesterol absorption and down regulation of Npc1l1, 
but did not affect the ability of  T0901317 to elevate serum HDL-cholesterol or the  
intestinal Abca1 mRNA levels [128]. It is thus unlikely that the LXR driven increase in 
HDL-cholesterol is directly dependent on the uptake of cholesterol in the small 
intestine. We did however observe decreased cholesterol levels in the intestinal tissue 
after GW3965+ezetimibe treatment and it is possible that long-term treatment with this 
combination may result in further cholesterol depletion of intestinal cells, which in turn 
may affect the HDL-cholesterol levels in the long run. Ezetimibe treatment has, 
however, been shown to induce intestinal cholesterol synthesis and LDL-receptor 
expression [129], compensating for the loss of NPC1L1-mediated uptake. 
 
The induction of hepatic ApoaI represents an interesting, anti-atherosclerotic effect that 
should be further investigated. The mechanism for this up regulation is unclear since 
ApoaI is not recognised as a direct LXR target gene. The opposing regulatory effects of 
LXR/FXR may hold the answer, as stimulation of FXR was reported to reduce ApoaI 
expression through a direct negative response element [67] and LXR activation was 
reported to reduce Cyp8b1 and CA/βMCA ratio in mice [42], which could lead to 
reduced FXR suppression. The LXR induced increase in ApoaI may thus be indirectly 
mediated through loss of FXR suppression, but this mechanism needs further 
evaluation. It also remains to be shown whether the induced transcription also increases 
ApoAI secretion.  
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The suggestion of a mechanism where increased HDL-cholesterol levels are 
independent of increased ABCA1 expression is somewhat controversial, since 
functional ABCA1 is crucial for HDL-formation and overexpression of ABCA1 
generally increases HDL-cholesterol in mice [130, 131]. The ABCA1 activity is 
however ATP dependent (ABCA1 is an ATPase) and regulated by phospholipid 
composition and cholesterol levels [132], meaning that the same amount of functional 
protein is likely to elicit different levels of activity depending on the cells lipid status. 
 
Paper IV 
 
MDS and mitochondrial fatty acid oxidation disorders are heterogeneous groups of 
disorders. Better understanding of the effects of mtDNA depletion in different organs 
and why symptoms differ is necessary for future development of optimal treatments. In 
paper IV we investigated the effect of mtDNA depletion on hepatic fatty acid 
metabolism. We aimed at describing the lipid phenotype of TK2 deficient mice in an 
attempt to find new possible treatment strategies and to better characterize this mouse 
model. 
 
The progressive loss of mtDNA in livers of TK2 deficient mice was apparent after 
post-natal day seven, around the same time when the symptoms of TK2 deficiency 
became visible. The TK2 deficient mice displayed symptoms like those of long-chain 
acyl-CoA mitochondrial β-oxidation disorders. The accumulation of long-chain 
acylcarnitines and increased free fatty acid levels in plasma of TK2 deficient mice 
suggested disturbances in CPT or LCAD activities. The observation of symptoms 
common for CPT or LCAD deficiency and the partial reduction in CPT activity in TK2 
deficient mice suggests involvement of several steps in the β-oxidation pathway of 
long-chain fatty acids. Since both Lcad and CptIa-c and II genes are located in the 
nuclear genome, the mtDNA depletion and transcriptional effects on the mitochondrial 
genome do not explain these defects, but it is likely that the hypertrophy of hepatic 
mitochondria leads to structural changes in the membranes that may reduce enzyme 
activity. We did not detect any significant reduction of the mitochondrial ATP 
production rates in 14 days old TK2 deficient mice and COXII protein expression was 
normal in 12 days old mice, indicating that the expression and function of 
mitochondrial proteins involved in the citric acid cycle or electron transfer chain were 
not primarily affected. 
 
Dietary restriction of fatty acid content to medium-chain fatty acids could be beneficial 
for TK2 deficient mice. Glucose supplementation may not increase survival if the fatty 
acid oxidation defect has similar basis as LCAD or CPT deficiency, but may improve 
brain function. The effect on survival by dietary interventions may however be limited 
by the progressive loss of mtDNA and the multi-organ involvement in TK2 deficiency. 
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6 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES  
 
This thesis describes some possible future approaches to modulate hepatic and 
intestinal lipid homeostasis with the aim of treating some specific lipid disorders; 
atherosclerosis and defect β-oxidation due to mtDNA depletion. Evaluation of the 
effects of total disruption of an enzyme may give important information on processes 
that are affected by the specific protein and its products, and this is one step in finding 
possible drug targets.  
 
Paper I described the effect of CA depletion on atherosclerosis in male mice; the 
plasma lipid-lowering effect and atherosclerosis reduction was associated with reduced 
intestinal cholesterol absorption. CA depletion is thus anti-atherosclerotic and lipid-
lowering in mice. Interestingly, the immunohistological examination of plaques from 
DKO mice showed a slight increase in CD68 stained area/plaque area and elevated 
mean numbers (although not statistically significant) of CD3+ and IA+ cells compared 
to ApoE mice, indicating that monocyte and T-cell infiltration may have been increased 
in DKO mice. Considering that CA depletion leads to increased bile acid pool and 
possibly increased levels of circulating bile acids in serum, the effect of CA depletion 
on the immune response and immune cell recruitment to the vascular wall should be 
more closely investigated. Furthermore, since FXR deficiency in mice has been 
reported to affect atherosclerosis development differently in male or female mice, 
studies on female CA depleted mice as well as studies of CA depletion in LDL-receptor 
deficient mice should be considered. In fact, preliminary data on female CYP8B1 
deficient mice fed an atherogenic diet suggest that CA depletion has a pronounced anti-
atherosclerotic effect on plasma lipoproteins that is gender-specific. The loss of hepatic 
FXR suppression in CA depleted mice may also increase hepatic ApoaI expression and 
secretion. Therefore, HDL metabolism should be more closely evaluated in these mice.  
 
Paper II described the effect of TRβ-specific modulation by GC-1 on atherosclerosis.  
Atherosclerosis was reduced after 20 weeks of GC-1 treatment, despite a transient 
effect on serum cholesterol. The effect of GC-1 on hepatic VLDL secretion, intestinal 
cholesterol absorption and RCT remain to be determined, but measurements of these 
parameters will add greatly to the understanding of the GC-1 mediated effect on 
atherosclerosis. Furthermore, investigations of the immunological response to GC-1 
treatment should be considered, since the TRβ-selective modulator KB3495 was 
recently observed to reduce macrophage content in aortic plaques and several 
inflammatory cytokines in serum ([78] and P. Parini personal communication). Also in 
this study, only male mice were used and GC-1 must be administered to females to 
complete the evaluation of this substance. 
 
Paper III described the effect on HDL-cholesterol by combined treatment with 
GW3965 and ezetimibe. We concluded that HDL-cholesterol levels were not correlated 
with intestinal cholesterol absorption and that the LXR driven increase in HDL-
   35 
cholesterol was independent of both intestinal cholesterol absorption and ABCA1 
protein expression. The proposed mechanism of induced hepatic ApoaI needs to be 
further evaluated and ApoAI secretion should be measured, preferably also the 
synthesis rate. Interestingly, T0901317 has been reported to increase ApoaI in intestinal 
cells and lymph [133], but since this LXR agonist is also a very potent PXR agonist 
[134], it is uncertain whether this effect is actually mediated directly through LXR. 
Also here, investigations of gender effects should be considered.  
 
The use of LXR agonists in human medicine with the intention of increasing HDL-
cholesterol is limited by the risk of increasing LDL-cholesterol. Combination of LXR 
stimulation with ezetimibe therapy, which lowers LDL-cholesterol may therefore 
compensate for this, but this must be tested in CETP expressing species. The anti-
atherosclerotic effects of LXR are however not limited to cholesterol metabolism. 
Several studies have indicated inflammatory or immune regulatory roles for LXR 
[135]. The effects on HDL retention and functionality by the GW3965+ezetimibe 
treatment should be further investigated.    
 
Paper IV described the effect of TK2 deficiency induced mtDNA depletion on hepatic 
β-oxidation. We concluded that TK2 deficiency in mice results in some symptoms that 
resemble mitochondrial long-chain fatty acid oxidation disorders. TK2 deficient mice 
could benefit from a fatty acid restricted diet, but this strategy is unlikely to save them 
from the continuous mtDNA depletion that will progress in resting cells, especially in 
the brain. To rescue the cells from mitochondrial dNTP depletion, induction of TK1 
activity could be considered. However, stimulation of transcription factors that regulate 
TK1 expression is likely to induce cell-proliferation and increase the risk of tumor 
development. Therefore, it would be necessary to develop a technique which allowed 
for specific induction of TK1 or stabilization from proteasomal degradation.  
 
Despite the apparent differences between species, mouse models have become valuable 
tools in medical research, especially because of the many possibilities of gene 
manipulation. Results from studies performed in species other than humans must 
always be valued with care, but as more and more knowledge about species differences 
are acquired, animal models can be increasingly refined.   
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